Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer

Cancer

Volumn 118, Issue 8, 2012, Pages 2059-2068

  Kapadia, Nirav S ^a   Olson, Karin ^a   Sandler, Howard M ^b   Feng, Felix Y ^a,c   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Ann Arbor Veteran Affairs Medical System   (United States)

Author keywords

biomarker; cause specific survival; prostate specific antigen; risk factors; surrogate

Indexed keywords

ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERVAL TO BIOCHEMICAL FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MORTALITY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; UNITED STATES;

AGED; COHORT STUDIES; EUKARYOTIC INITIATION FACTOR-3; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTORS; TREATMENT FAILURE;

EID: 84859648617     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26498     Document Type: Article

References (27)

1. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
2. Scherr D, Swindle PW, Scardino PT,. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003; 61: 14-24.
3. Cox G, Kaplan G, for the American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 1035-1041.
4. Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006; 64: 1140-1150.
5. Horwitz EM, Vicini F, Ziaja EL, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 1996; 36: 565-571.
6. Hanlon AL, Diratzouian H, Hanks GE,. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 2002: 297-303.
7. DeWitt KD, Sandler HM, Weinberg V, et al. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology. 2003; 62: 492-496.
8. Crook JM, Bahadur YA, Bociek RG, et al. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer. 1997; 79: 328-336.
9. Lee WR, Hanlon AL, Hanks GE,. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol. 1996; 156 (2 pt 1): 450-453.
10. D'Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004; 172: S42-S47.
11. D'Amico AV, Moul J, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95: 1376-1383.
12. Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2006; 23: 826-831.
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597.
14. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A,. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 59-66.
15. Buyyounouski MK, Pickles T, Kestin L, Allison R, Williams SG,. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 75: S103-S104.
16. Denham JW, Stiegler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008; 9: 1058-1068.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
18. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study), a phase III randomized trial. Lancet. 2002; 360: 103.
19. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomaa-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290.
20. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
21. Moul JW, Banez LL, Freedland SJ,. Rising PSA in nonmetastatic prostate cancer. Oncology. 2007; 21: 1436-1454.
22. Walsh PC, Deweese TL, Eisenberger MA,. A structured debate: immediate versus deferred androgen suppression in prostate cancera-evidence for deferred treatment. J Urol. 2001; 166: 508-516.
23. Souhami L, Bae K, Pilepich M, Sandler H,. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys. 2010; 78: 1301-1306.
24. Shipley WU, Desilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006; 64: 1162-1167.
25. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.
26. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R,. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol. 2008; 180: 1438-1444.
27. D'Ambrosio DJ, Ruth K, Buyyounouski MK, Horwitz EM, Uzzo RG, Pollack A,. Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. Int J Radiat Oncol Biol Phys. 2006; 66: S334-S335.